Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From AnGes Inc.

Coronavirus Update: Sinovac Gets $15m Towards CoronaVac Phase II, Remdesivir Early Access In UK

Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares. 

Coronavirus COVID-19 BioPharmaceutical

Japan To Reimburse Zolgensma – But At Lower Price Than US

Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.

Japan Gene Therapy

Japan To Reimburse Zolgensma – But At Lower Price Than US

Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.

Japan Gene Therapy

New Drug Launches Worldwide Dipped In 2019

The number of new active substances launched in their first market in 2019 dropped as 2018’s superlative performance gave way to something more usual.

Companies Innovation
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • MedGene Bioscience Inc.
  • AnGes MG Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • AnGes Inc.
  • Senior Management
  • Ei Yamada, Pres. & CEO
  • Contact Info
  • AnGes Inc.
    Phone: (81)
    4F Saito Bio-Incubator
    Ibaraki
    Osaka, 567-0085
    Japan
UsernamePublicRestriction

Register